Oral Rivaroxaban for Symptomatic Venous Thromboembolism
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring. METHODS: We conducted an open-label, randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous enoxaparin followed by a vitamin K antagonist (either warfarin or acenocoumarol) for 3, 6, or 12 months in patients with acute, symptomatic DVT. In parallel, we carried out a double-blind, randomized, event-driven superiority study that compared rivaroxaban alone (20 mg once daily) with placebo for an additional 6 or 12 months in patients who had completed 6 to 12 months of treatment for venous thromboembolism. The primary efficacy outcome for both studies was recurrent venous thromboembolism. The principal safety outcome was major bleeding or clinically relevant nonmajor bleeding in the initial-treatment study and major bleeding in the continued-treatment study. RESULTS: The study of rivaroxaban for acute DVT included 3449 patients: 1731 given rivaroxaban and 1718 given enoxaparin plus a vitamin K antagonist. Rivaroxaban had noninferior efficacy with respect to the primary outcome (36 events [2.1%], vs. 51 events with enoxaparin-vitamin K antagonist [3.0%]; hazard ratio, 0.68; 95% confidence interval [CI], 0.44 to 1.04; P<0.001). The principal safety outcome occurred in 8.1% of the patients in each group. In the continued-treatment study, which included 602 patients in the rivaroxaban group and 594 in the placebo group, rivaroxaban had superior efficacy (8 events [1.3%], vs. 42 with placebo [7.1%]; hazard ratio, 0.18; 95% CI, 0.09 to 0.39; P<0.001). Four patients in the rivaroxaban group had nonfatal major bleeding (0.7%), versus none in the placebo group (P=0.11). CONCLUSIONS: Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation. (Funded by Bayer Schering Pharma and Ortho-McNeil; ClinicalTrials.gov numbers, NCT00440193 and NCT00439725.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [88]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [88]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [88]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [88]
Citations
Cites
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
The Long-Term Clinical Course of Acute Deep Venous Thrombosis
Prandoni, P., Lensing, A. W. A., Cogo, A., Cuppini, S., Villalta, S., Carta, M., Cattelan, A. M., Polistena, P., Bernardi, E., & Prins, M. H. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00001 · Cited by 2,109
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445
Turpie, A. G., Lassen, M. R., Davidson, B. L., Bauer, K. A., Gent, M., Kwong, L. M., Cushner, F. D., Lotke, P. A., Berkowitz, S. D., Bandel, T. J., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60734-0 · Cited by 981
In-Stent Restenosis in the Drug-Eluting Stent Era
Dangas, G. D., Claessen, B. E., Caixeta, A., Sanidas, E. A., Mintz, G. S., & Mehran, R. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.07.028 · Cited by 803
Incidence of Venous Thromboembolism: A Community-based Study in Western France
Oger, E., & the EPI-GETBO Study Group (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613887 · Cited by 711
KUBITZA, D., BECKA, M., VOITH, B., ZUEHLSDORF, M., & WENSING, G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.011 · Cited by 649
Rodger, M. A., Kahn, S. R., Wells, P. S., Anderson, D. A., Chagnon, I., Le Gal, G., Solymoss, S., Crowther, M., Perrier, A., White, R., et al. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080493 · Cited by 581
Research works printed but not linked: 1
- Hutten BA, 2006, Cochrane Database Syst Rev, 1, CD001367
Cited by
Items 101–200 of 1,010
Kubitza, D., Roth, A., Becka, M., Alatrach, A., Halabi, A., Hinrichsen, H., & Mueck, W. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12054 · Cited by 205
New Oral Anticoagulants and the Cancer Patient
Short, N. J., & Connors, J. M. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0239 · Cited by 204
Anticoagulants: A Review of the Pharmacology, Dosing, and Complications
Alquwaizani, M., Buckley, L., Adams, C., & Fanikos, J. (2013) · Current Emergency and Hospital Medicine Reports · doi:10.1007/s40138-013-0014-6 · Cited by 201
Twine, C. P., Kakkos, S. K., Aboyans, V., Baumgartner, I., Behrendt, C.-A., Bellmunt-Montoya, S., Jilma, B., Nordanstig, J., Saratzis, A., Reekers, J. A., et al. (2023) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2023.03.042 · Cited by 197
Agewall, S., Cattaneo, M., Collet, J. P., Andreotti, F., Lip, G. Y. H., Verheugt, F. W. A., Huber, K., Grove, E. L., Morais, J., Husted, S., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht042 · Cited by 202
Sterne, J. A., Bodalia, P. N., Bryden, P. A., Davies, P. A., López-López, J. A., Okoli, G. N., Thom, H. H., Caldwell, D. M., Dias, S., Eaton, D., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21090 · Cited by 198
Cohen, A. T., Hamilton, M., Mitchell, S. A., Phatak, H., Liu, X., Bird, A., Tushabe, D., & Batson, S. (2015) · PLOS ONE · doi:10.1371/journal.pone.0144856 · Cited by 198
Adam, S. S., McDuffie, J. R., Ortel, T. L., & Williams, J. W. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-10-201211200-00532 · Cited by 194
Streiff, M. B., Holmstrom, B., Angelini, D., Ashrani, A., Buckner, T., Diep, R., Fertrin, K. Y., Fogerty, A. E., Crestani, N. G., Gangaraju, R., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0046 · Cited by 184
Castellucci, L. A., Cameron, C., Le Gal, G., Rodger, M. A., Coyle, D., Wells, P. S., Clifford, T., Gandara, E., Wells, G., & Carrier, M. (2013) · BMJ · doi:10.1136/bmj.f5133 · Cited by 193
Chai‐Adisaksopha, C., Hillis, C., Isayama, T., Lim, W., Iorio, A., & Crowther, M. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13139 · Cited by 190
Kahn, S. R. (2010) · Hematology · doi:10.1182/asheducation-2010.1.216 · Cited by 190
Deep vein thrombosis: update on diagnosis and management
Kruger, P. C., Eikelboom, J. W., Douketis, J. D., & Hankey, G. J. (2019) · Medical Journal of Australia · doi:10.5694/mja2.50201 · Cited by 188
Nicolaides, A., Fareed, J., Kakkar, A. K., Comerota, A. J., Goldhaber, S. Z., Hull, R., Myers, K., Samama, M., Fletcher, J., Kalodiki, E., et al. (2013) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029612474840 · Cited by 185
Laliberté, F., Cloutier, M., Nelson, W. W., Coleman, C. I., Pilon, D., Olson, W. H., Damaraju, C. V., Schein, J. R., & Lefebvre, P. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.907140 · Cited by 185
Treatment of cancer-associated thrombosis
Lee, A. Y. Y., & Peterson, E. A. (2013) · Blood · doi:10.1182/blood-2013-04-460162 · Cited by 183
Sié, P., Samama, C. M., Godier, A., Rosencher, N., Steib, A., Llau, J. V., Van der Linden, P., Pernod, G., Lecompte, T., Gouin-Thibault, I., et al. (2011) · Archives of Cardiovascular Diseases · doi:10.1016/j.acvd.2011.09.001 · Cited by 183
Steiner, T., Böhm, M., Dichgans, M., Diener, H.-C., Ell, C., Endres, M., Epple, C., Grond, M., Laufs, U., Nickenig, G., et al. (2013) · Clinical Research in Cardiology · doi:10.1007/s00392-013-0560-7 · Cited by 183
Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes
Khairani, C. D., Bejjani, A., Piazza, G., Jimenez, D., Monreal, M., Chatterjee, S., Pengo, V., Woller, S. C., Cortes-Hernandez, J., Connors, J. M., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.10.008 · Cited by 172
Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis
Tripodi, A., Primignani, M., Lemma, L., Chantarangkul, V., & Mannucci, P. M. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.03.036 · Cited by 178
Carrier, M., Khorana, A. A., Zwicker, J. I., Noble, S., & Lee, A. Y. Y. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12338 · Cited by 174
Yaghi, S. R., Shu, L., Bakradze, E., Omran, S. S., Giles, J. A., Amar, J. Y., Henninger, N., Elnazeir, M., Liberman, A. L., Moncrieffe, K., et al. (2022) · Stroke · doi:10.1161/strokeaha.121.037541 · Cited by 190
Carrier, M., Cameron, C., Delluc, A., Castellucci, L., Khorana, A. A., & Lee, A. Y. Y. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.09.039 · Cited by 172
Almutairi, A. R., Zhou, L., Gellad, W. F., Lee, J. K., Slack, M. K., Martin, J. R., & Lo-Ciganic, W.-H. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.05.358 · Cited by 171
Keragala, C. B., Draxler, D. F., McQuilten, Z. K., & Medcalf, R. L. (2018) · British Journal of Haematology · doi:10.1111/bjh.15062 · Cited by 170
Bosch, J., Eikelboom, J. W., Connolly, S. J., Bruns, N. C., Lanius, V., Yuan, F., Misselwitz, F., Chen, E., Diaz, R., Alings, M., et al. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.06.001 · Cited by 161
Narouze, S., Benzon, H. T., Provenzano, D., Buvanendran, A., De Andres, J., Deer, T., Rauck, R., & Huntoon, M. A. (2017) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000700 · Cited by 164
Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor
Kreutz, R., Llau, J., Norrving, B., Haas, S., & Turpie, A. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-03-0209 · Cited by 168
Mueck, W., Schwers, S., & Stampfuss, J. (2013) · Thrombosis Journal · doi:10.1186/1477-9560-11-10 · Cited by 165
Kitchen, S., Gray, E., Mackie, I., Baglin, T., Makris, M., & the BCSH committee (2014) · British Journal of Haematology · doi:10.1111/bjh.12975 · Cited by 167
Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism
Planquette, B., Bertoletti, L., Charles-Nelson, A., Laporte, S., Grange, C., Mahé, I., Pernod, G., Elias, A., Couturaud, F., Falvo, N., et al. (2022) · Chest · doi:10.1016/j.chest.2021.09.037 · Cited by 163
Johnson, J. A., & Cavallari, L. H. (2015) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2014.09.001 · Cited by 164
Cohen, H., Cuadrado, M. J., Erkan, D., Duarte‐García, A., Isenberg, D. A., Knight, J. S., Ortel, T. L., Rahman, A., Salmon, J. E., Tektonidou, M. G., et al. (2020) · Lupus · doi:10.1177/0961203320950461 · Cited by 181
Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism
Witt, D. M., Clark, N. P., Kaatz, S., Schnurr, T., & Ansell, J. E. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1319-y · Cited by 161
“Little is known about the use of DOACs in patients with an estimated CrCl\ 30 mL/min, as these patients were excluded from clinical trials comparing DOACs to warfarin for VTE treatment [14–20].”
BackgroundCastellucci, L. A., Cameron, C., Le Gal, G., Rodger, M. A., Coyle, D., Wells, P. S., Clifford, T., Gandara, E., Wells, G., & Carrier, M. (2014) · JAMA · doi:10.1001/jama.2014.10538 · Cited by 162
Acute management of bleeding in patients on novel oral anticoagulants
Siegal, D. M., & Crowther, M. A. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs408 · Cited by 166
Dufrost, V., Risse, J., Reshetnyak, T., Satybaldyeva, M., Du, Y., Yan, X.-X., Salta, S., Gerotziafas, G., Jing, Z.-C., Elalamy, I., et al. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.04.009 · Cited by 161
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2011) · New England Journal of Medicine · doi:10.1056/nejmc1100734 · Cited by 159
Introduction to the Ninth Edition
Guyatt, G. H., Akl, E. A., Crowther, M., Schünemann, H. J., Gutterman, D. D., & Lewis, S. Z. (2012) · Chest · doi:10.1378/chest.11-2286 · Cited by 159
Raskob, G. E., van Es, N., Segers, A. E. M., Angchaisuksiri, P., Oh, D., Boda, Z., Lyons, R. M., Meijer, K., Gudz, I., Weitz, J. I., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)30057-6 · Cited by 167
van der Hulle, T., den Exter, P. L., Kooiman, J., van der Hoeven, J. J. M., Huisman, M. V., & Klok, F. A. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12605 · Cited by 164
Hospital Costs of Acute Pulmonary Embolism
Fanikos, J. R., Rao, A. F., Seger, A. C., Carter, D., Piazza, G., & Goldhaber, S. Z. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.07.025 · Cited by 161
Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer
Kahale, L. A., Hakoum, M. B., Tsolakian, I. G., Alturki, F., Matar, C. F., Terrenato, I., Sperati, F., Barba, M., Yosuico, V. E. D., Schünemann, H. J., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006650.pub5 · Cited by 170
Schrag, D., Uno, H., Rosovsky, R. P. G., Rutherford, C., Sanfilippo, K. M., Villano, J. L., Drescher, M. R., Jayaram, N. H., Holmes, C. E., Feldman, L. E., et al. (2023) · JAMA · doi:10.1001/jama.2023.7843 · Cited by 166
2014 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism
Konstantinides, S., Torbicki, A., Agnelli, G., Danchin, N., Fitzmaurice, D. A., Galiè, N., Gibbs, J. S. R., Huisman, M., Humbert, M. J. C., Kucher, N., et al. (2014) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2014.12.002 · Cited by 153
Young, A., Chapman, O., Connor, C., Poole, C., Rose, P., & Kakkar, A. K. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.106 · Cited by 150
Dose-Finding Study of Rivaroxaban in Hemodialysis Patients
Vriese, A. S. D., Caluwé, R., Bailleul, E., Bacquer, D. D., Borrey, D., Vlem, B. V., Vandecasteele, S. J., & Emmerechts, J. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.01.022 · Cited by 163
Reversal of anticoagulants: an overview of current developments
Thiele, T., Selleng, K., & Greinacher, A. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-11-0982 · Cited by 161
Targeting factor Xa and thrombin: impact on coagulation and beyond
Esmon, C. T. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-09-0730 · Cited by 149
Agnelli, G., Becattini, C., Bauersachs, R., Brenner, B., Campanini, M., Cohen, A., Connors, J., Fontanella, A., Gussoni, G., Huisman, M., et al. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1668523 · Cited by 146
Management of portal vein thrombosis in liver cirrhosis
Qi, X., Han, G., & Fan, D. (2014) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2014.36 · Cited by 145
Khan, F. A., Tritschler, T., Kimpton, M., Wells, P. S., Kearon, C., Weitz, J. I., Buller, H. R., Raskob, G. E., Ageno, W., Couturaud, F., et al. (2021) · Annals of Internal Medicine · doi:10.7326/m21-1094 · Cited by 162
Chitsike, R. S., Rodger, M. A., Kovacs, M. J., Betancourt, M. T., Wells, P. S., Anderson, D. R., Chagnon, I., Gal, G. L., Solymoss, S., Crowther, M. A., et al. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2012.04872.x · Cited by 154
Cohen, H., Arachchillage, D. J., Middeldorp, S., Beyer‐Westendorf, J., & Kadir, R. A. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13366 · Cited by 154
Davidson, B. L., Verheijen, S., Lensing, A. W. A., Gebel, M., Brighton, T. A., Lyons, R. M., Rehm, J., & Prins, M. H. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.946 · Cited by 141
Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy
Barra, M. E., Fanikos, J. R., Connors, J. M., Sylvester, K. W., Piazza, G., & Goldhaber, S. Z. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.05.041 · Cited by 150
Kushnir, M., Choi, Y., Eisenberg, R., Rao, D., Tolu, S., Gao, J., Mowrey, W., & Billett, H. H. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30086-9 · Cited by 137
Kakkos, S. K., Kirkilesis, G. I., & Tsolakis, I. A. (2014) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2014.05.001 · Cited by 138
Fox, B. D., Kahn, S. R., Langleben, D., Eisenberg, M. J., & Shimony, A. (2012) · BMJ · doi:10.1136/bmj.e7498 · Cited by 136
Miller, C., Dorreen, A., Martel, M., Huynh, T., & Barkun, A. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.04.031 · Cited by 138
Gómez‐Outes, A., Terleira‐Fernández, A. I., Lecumberri, R., Suárez‐Gea, M. L., & Vargas, E. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.06.020 · Cited by 148
Grilz, E., Posch, F., Nopp, S., Königsbrügge, O., Lang, I. M., Klimek, P., Stefan Thurner, A., Pabinger, I., & Ay, C. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab171 · Cited by 143
Andreozzi, G. M., Bignamini, A. A., Davì, G., Palareti, G., Matuška, J., Holý, M., Pawlaczyk-Gabriel, K., Džupina, A., Юрьевич, С. Г., Didenko, Y. P., et al. (2015) · Circulation · doi:10.1161/circulationaha.115.016930 · Cited by 138
Lutz, J., Jurk, K., & Schinzel, H. (2017) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s105771 · Cited by 143
Alfonso, A., Jiménez, D., Capitán, C. F., Prandoni, P., Wells, P. S., Vidal, G., Barillari, G., Monreal, M., Lecumberri, R., & and the RIETE Investigators (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-02-0132 · Cited by 129
Pulmonary embolism: risk assessment and management
Konstantinides, S., & Goldhaber, S. Z. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs258 · Cited by 137
Romualdi, E., Donadini, M. P., & Ageno, W. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.62 · Cited by 129
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Pearson, S., Troughton, R., & Richards, A. M. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1112233 · Cited by 130
Why do we need observational studies of everyday patients in the real-life setting?: Table 1
Cohen, A. T., Goto, S., Schreiber, K., & Torp-Pedersen, C. (2015) · European Heart Journal Supplements · doi:10.1093/eurheartj/suv035 · Cited by 125
Elsebaie, M. A., van Es, N., Langston, A. A., Buller, H. R., & Gaddh, M. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14398 · Cited by 142
Update on Guidelines for the Management of Cancer-Associated Thrombosis
Streiff, M. B., Abutalib, S. A., Farge, D., Murphy, M. C., Connors, J. M., & Piazza, G. (2020) · The Oncologist · doi:10.1002/onco.13596 · Cited by 143
Pharmacodynamic and pharmacokinetic basics of rivaroxaban
Kreutz, R. H. (2011) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2011.00981.x · Cited by 126
Graff, J., & Harder, S. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0034-0 · Cited by 129
“For treatment of VTE and pulmonary embolism the dose range is 15–20 mg once daily (initially 15 mg twice daily) [50, 51], and for the prevention of stroke in patients with atrial fibrillation the dose range is 15–20 mg once daily [52].”
BackgroundEvolving use of new oral anticoagulants for treatment of venous thromboembolism
Yeh, C. H., Gross, P. L., & Weitz, J. I. (2014) · Blood · doi:10.1182/blood-2014-03-563056 · Cited by 127
Ballestri, S., Romagnoli, E., Arioli, D., Coluccio, V., Marrazzo, A., Athanasiou, A., Girolamo, M. D., Cappi, C., Marietta, M., & Capitelli, M. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02333-9 · Cited by 148
Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates
Gruber, A., Tinel, H., Marzec, U. M., Buetehorn, U., Buchmüller, A., Heitmeier, S., Laux, V., & Perzborn, E. (2013) · Thrombosis and Haemostasis · doi:10.1160/th12-12-0907 · Cited by 125
Meeting the challenge of corporate entrepreneurship.
Garvin, D. A., & Levesque, L. (2006) · PubMed · Cited by 193
Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT)
Connor, P., van Kammen, M. S., Lensing, A. W. A., Chalmers, E. A., Kállay, K. M., Hege, K. M., Simioni, P., Biss, T. T., Bajolle, F., Bonnet, D., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020003244 · Cited by 130
Venous thromboembolism in cancer patients: an underestimated major health problem
Khalil, J., Bensaid, B., Elkacemi, H., Afif, M., Bensaïd, Y., Kebdani, T., & Benjaafar, N. (2015) · World Journal of Surgical Oncology · doi:10.1186/s12957-015-0592-8 · Cited by 126
Stubbs, M. J., Mouyis, M., & Thomas, M. R. (2018) · BMJ · doi:10.1136/bmj.k351 · Cited by 151
Zhou, Q., Bea, F., Preusch, M. R., Wang, H., Isermann, B., Shahzad, K., Katus, H. A., & Blessing, E. (2011) · Mediators of Inflammation · doi:10.1155/2011/432080 · Cited by 124
Hemostatic Therapy in Experimental Intracerebral Hemorrhage Associated With Rivaroxaban
Zhou, W., Zorn, M., Nawroth, P. P., Buetehorn, U., Perzborn, E., Heitmeier, S., & Veltkamp, R. C. (2013) · Stroke · doi:10.1161/strokeaha.112.675231 · Cited by 118
“Its widespread clinical use beyond stroke prevention in atrial fibrillation is expected because it has been proven effective and safe for additional indications, including acute coronary syndrome and venous thromboembolism.(17,18) So far, no specific antidote for rivaroxaban is available, and the efficacy of hemostati…”
BackgroundPrevention, Diagnostics and Treatment of Deep Vein Thrombosis. Russian Experts Consensus
Seliverstov, E. I., Lobastov, K. V., Ilyukhin, Е. А., Apkhanova, T. V., Akhmetzyanov, R. V., Akhtyamov, I. F., Barinov, V., Bakhmetiev, A. S., Belov, M. V., Александрович, Б. С., et al. (2023) · Journal of Venous Disorders · doi:10.17116/flebo202317031152 · Cited by 121
Creager, M. A., Barnes, G. D., Giri, J., Mukherjee, D., Jones, W. S., Burnett, A. E., Carman, T., Casanegra, A. I., Castellucci, L. A., Clark, S. M., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.11.005 · Cited by 145
Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location
Janczak, D. T., Mimier, M. K., McBane, R. D., Kamath, P. S., Simmons, B. S., Bott‐Kitslaar, D. M., Lenz, C. J., Vargas, E. R., Hodge, D. O., & Wysokiński, W. E. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.10.007 · Cited by 118
Olaf, M. F., & Cooney, R. R. (2017) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2017.06.003 · Cited by 138
Kubitza, D., Becka, M., Roth, A., & Mueck, W. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.5 · Cited by 116
Oral Direct Factor Xa Inhibitors
Yeh, C. H., Fredenburgh, J. C., & Weitz, J. I. (2012) · Circulation Research · doi:10.1161/circresaha.112.276741 · Cited by 131
How I treat target-specific oral anticoagulant–associated bleeding
Siegal, D. M., Garcia, D. A., & Crowther, M. A. (2014) · Blood · doi:10.1182/blood-2013-09-529784 · Cited by 121
Perioperative management of patients on direct oral anticoagulants
Dubois, V., Dincq, A.-S., Douxfils, J., Ickx, B., Samama, C. M., Dogné, J., Gourdin, M. J., Châtelain, B., Mullier, F., & Lessire, S. (2017) · Thrombosis Journal · doi:10.1186/s12959-017-0137-1 · Cited by 122
Klok, F. A., Kooiman, J., Huisman, M. V., Konstantinides, S., & Lankeit, M. (2014) · European Respiratory Journal · doi:10.1183/09031936.00040714 · Cited by 117
Management of antiphospholipid syndrome
Uthman, I. W., Noureldine, M. H. A., Ruiz‐Irastorza, G., & Khamashta, M. A. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-213846 · Cited by 125
Evolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral Anticoagulants
Chan, N., Eikelboom, J. W., & Weitz, J. I. (2016) · Circulation Research · doi:10.1161/circresaha.116.306925 · Cited by 125
Couturaud, F., Schmidt, J., Sanchez, O., Ballerie, A., Sevestre, M., Meneveau, N. F., Bertoletti, L., Connault, J., Benhamou, Y., Constans, J., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02842-3 · Cited by 118
Non‐adherence to new oral anticoagulants: a reason for concern during long‐term anticoagulation?
Rodriguez, R. A., Carrier, M., & Wells, P. S. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12086 · Cited by 122
Yamada, N., Hirayama, A., Maeda, H., Sakagami, S., Shikata, H., Prins, M. H., Lensing, A. W. A., Kato, M. C., Onuma, J., Miyamoto, Y., et al. (2015) · Thrombosis Journal · doi:10.1186/s12959-015-0035-3 · Cited by 110
Girgis, I. G., Patel, M. R., Peters, G. R., Moore, K. T., Mahaffey, K. W., Nessel, C. C., Halperin, J. L., Califf, R. M., Fox, K. A. A., & Becker, R. C. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.288 · Cited by 111
Vascular Thoracic Outlet Syndrome
Hussain, M. A., Aljabri, B. A., & Al-Omran, M. A. (2015) · Seminars in Thoracic and Cardiovascular Surgery · doi:10.1053/j.semtcvs.2015.10.008 · Cited by 108
Cano, S., Lamping, D. L., Bamber, L., & Smith, S. C. (2012) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-10-120 · Cited by 118
Edoxaban: A New Oral Direct Factor Xa Inhibitor
Camm, A. J., & Bounameaux, H. (2011) · Drugs · doi:10.2165/11595540-000000000-00000 · Cited by 112
“D ru g s 2 0 1 1 AVERROES (Apixaban VERsus acetylsalicylic acid to pRevent strOkES) study,[68,69] in patients with AF, and the ROCKET AF (Rivaroxaban Once daily, oral, direct Factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) study,[32-34,67] as…”
Influential
Metadata
- Authors
- The EINSTEIN Investigators
- Corresponding author
- The EINSTEIN Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-12-23
- Volume
- 363
- Issue
- 26
- Pages
- 2499-2510
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2115787552
- Cited by
- 3,237
- References
- 19
- Citations by year
- 2026: 90 · 2025: 105 · 2024: 118 · 2023: 153 · 2022: 169 · 2021: 189 · 2020: 261 · 2019: 242 · 2018: 248 · 2017: 232 · 2016: 300 · 2015: 267 · 2014: 290 · 2013: 255 · 2012: 188
- FWCI
- 148.86
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- Pure Amsterdam UMC (publishedVersion)
- ORBi (University of Liège) (acceptedVersion, other-oa)
- Murdoch University Research Portal (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- DIAL (Catholic University of Leuven) (submittedVersion)
- Flinders Academic Commons (Flinders University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- IrInSubria (University of Insubria) (submittedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Research Publications (Maastricht University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- rivaroxaban, oral factor Xa inhibitors, venous thromboembolism, deep vein thrombosis, continuation treatment, recurrent venous thromboembolism, enoxaparin, vitamin K antagonists, warfarin, acenocoumarol, major bleeding, non-inferiority
- MeSH terms
- Rivaroxaban, Acenocoumarol, Acute Disease, Administration, Oral, Aged, Anticoagulants, Double-Blind Method, Female, Hemorrhage, Humans, Injections, Subcutaneous, Male, Middle Aged, Morpholines, Pulmonary Embolism, Thiophenes, Vitamin K, Warfarin, Enoxaparin, Venous Thrombosis, Kaplan-Meier Estimate, Venous Thromboembolism, Intention to Treat Analysis, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.